PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based approach. In only a few months, our new client experienced PRA’s commitment open communication and engaging relationships and our determination to meet critical deadlines. These qualities are now the foundation of our very successful partnership.
Strategies for Accelerating Rare Disease Clinical Development
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient…
PRA Revs Up Multiple Myeloma Study
A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug.…
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.